Based in France, Curlim is an innovative biotech company focused on developing therapeutic solutions for hereditary peripheral neuropathies and rare neurodegenerative diseases. These debilitating conditions, such as Charcot–Marie–Tooth disease (CMT), affect tens of thousands of patients in Europe and the U.S. and currently have no curative treatments. CMT, the most common inherited peripheral neuropathy, affects approximately 1 in 5,000 individuals worldwide representing a major unmet medical need for patients worldwide.

Curlim has developed an innovative encapsulation platform designed to improve the therapeutic efficacy of bioactive molecules for treating hereditary peripheral neuropathies and rare diseases. The benefits are better Solubility, better Stability, better Bioavailability and a significant increase of intra-cellular penetration (Trojan horse) allowing molecules to reach full therapeutic potential.

Curlim obtained unprecedented and spectacular therapeutic effects with significant rescue in the nerve function (demonstrated on 2 CMT1A animal models with no signs of toxicity, even with repeated doses. Some highlights : very significant improvement in Motor Nerve Conduction Velocities (MNCV) in all models and a normalisation of motor skills, with balance time on the bar not statistically different from normal rats.

Moreover, the platform is a flexible solution applicable to multiple drug candidates and therapeutic indications, far beyond neuropathies.

This makes Curlim not just a drug developer, but the owner of a scalable, high-value platform technology with long-term partnering and licensing potential.

Brenus Pharma is a French clinical-stage biotechnology company developing a new class of in vivo immunotherapies for solid tumors.

The company has built a proprietary, data-driven platform based on its Stimulated-Ghost-Cell (SGC) technology. It transforms tumor complexity into scalable, off-the-shelf therapeutic candidates by integrating multi-omics data, predictive validation models, and GMP-ready manufacturing. This approach enables cost control and broad patient access, overcoming key limitations of personalized therapies such as mRNA and CAR-T.

SGC technology reproduces tumor protein expression and makes these targets visible to the immune system. It captures tumor heterogeneity, including resistance and plasticity, and enables broad, multi-specific immune responses against evolving tumors.

The lead candidate, STC-1010, targets metastatic colorectal cancer, the second leading cause of cancer-related death worldwide. It is currently evaluated in a Phase I/II trial (NCT06934538) in advanced MSS CRC. Early data show a favorable safety profile and initial signs of immune engagement.

Upcoming milestones include U.S. IND submission, clinical data readouts, and a Series B financing.

Currently in phase I/II mCRC clinical trial with treatment initiated for the first patients, STC-1010 aims to address the high unmet need in first-line treatment of microsatellite stable colorectal cancer, where standard immunotherapies remain largely ineffective.

THX Pharma (ALTHX) is a listed biopharmaceutical company dedicated to discovering and developing treatments for rare neurological disorders. THX pharma has two lead assets TX01 and Batten-1:

TX01 is a proprietary, high-concentration oral solution built on an approved active ingredient, specifically formulated to address specific unmet needs in two rare lysosomal storage disorders: Niemann-Pick disease type C and Gaucher disease. THX Pharma (ALTHX) is currently finalizing its market authorization dossier for submission to both the EMA and FDA before year-end, with regional launches to follow across additional territories by 2027, and a projected revenue milestone of ~€50M by 2032. To accelerate patient access globally, the company has established two strategic licensing partnerships: Exeltis (Insud Pharma Group) holds exclusive commercialization rights across Europe, Latin America, and the MENA region, while Biocodex covers the United States and Canada. THX retains APAC rights and is actively seeking out-licensing partners to complete its global coverage.

Batten-1 is a proprietary, high-concentration oral liquid formulation of miglustat, optimized to meet the specific needs of pediatric and dysphagic patients with Batten disease — a devastating rare neurological disorder. Early clinical evidence is compelling: Phase I/II data demonstrated clear target engagement, reductions in neuronal death markers, and stabilization signals, while real-world data have shown clinically meaningful visual acuity stabilization. Both the FDA and EMA have endorsed a single pivotal Phase 3 pathway, streamlining the path to approval across major markets. THX Pharma (ALTHX) is currently advancing its Phase 3 program alongside an optimized Early Access strategy, underpinned by orphan designation and patent protection extending to ~2047 — providing a durable competitive moat. The global development and commercialization rights have been exclusively licensed to Biocodex, ensuring a well-resourced partner to drive the program through to launch and beyond. Peak revenue is modelled at ~€200M by 2033 across target markets.

Beyond its clinical-stage assets, THX Pharma can leverage a proprietary discovery platform to identify and develop next-generation drug candidates based on antisense oligonucleotide (ASO) technology. Two programs are currently underway:

The first targets TFEB, a transcription factor widely regarded as the master regulator of autophagy — the cellular recycling process by which cells clear damaged proteins and organelles. Dysregulation of autophagy is implicated in a broad spectrum of degenerative conditions, including Parkinson’s disease, Alzheimer’s disease, ALS, and Huntington’s disease, positioning TFEB modulation as a high-value therapeutic axis across neurology and beyond.

The second program is focused on characterizing an undisclosed target with promising therapeutic potential in glioblastoma — the most aggressive and lethal primary brain tumor in adults, with a median survival of under 15 months and fewer than 5% of patients alive at five years; approximately 300,000 new cases are diagnosed worldwide each year. Both programs are conducted in collaboration with leading French academic teams specializing in ASO therapeutics, and the TFEB project has received formal recognition through a France 2030 grant awarded by BPI France — validating both the scientific rationale and the quality of the research partnership.